Precision BioSciences Expands Leadership Team for Growth
Precision BioSciences, Inc. (Nasdaq: DTIL), a pioneering clinical-stage gene editing company, has made significant changes to its senior leadership team as it aims to advance its in vivo gene editing programs, including the promising PBGENE-HBV project currently in Phase 1 clinical studies.
Strategic Leadership Appointments
In her new role as Chief Development and Business Officer, Cindy Atwell will spearhead all developmental functions at Precision. This includes overseeing clinical, regulatory, and translational efforts while managing business development and alliances. Ms. Atwell joined Precision BioSciences in 2019 and became the Chief Business Officer in 2022. Her leadership has been crucial in forging multiple partnerships and successfully guiding the company’s business development initiatives.
Cindy Atwell's Background
Cindy Atwell has amassed over two decades of experience in the biopharma sector, with a robust background in clinical research and business development spanning previous roles at notable companies such as Halozyme and AbbVie. With an MBA from the University of California, San Diego, and a degree in biochemistry from the Pennsylvania State University, Cindy is well-equipped to lead Precision's growth efforts.
Strengthening Scientific Leadership
Additionally, Cassie Gorsuch, PhD, has been promoted to Chief Scientific Officer. Dr. Gorsuch will oversee non-clinical development and gene therapy discovery. Before her promotion, she served as Vice President of Gene Therapy Discovery, where she played a pivotal role in moving the PBGENE-HBV program from preclinical stages to clinical studies.
Dr. Gorsuch's Contributions
With a PhD in biological sciences from the University of Notre Dame and a Bachelor's degree in biochemistry from Rockhurst University, Dr. Gorsuch is tasked with ensuring that preclinical efforts translate into successful clinical outcomes. Her leadership will not only guide internal teams but also foster ongoing education and engagement regarding Precision’s innovative ARCUS gene editing technology.
Reaffirming Commitment and Future Endeavors
CEO Michael Amoroso expressed pride in promoting Cindy Atwell, noting her critical role in achieving regulatory milestones through strategic partnerships. He emphasized the company’s commitment to evolving as a leader in in vivo gene editing, starting with the PBGENE-HBV program, which is expected to yield clinical data milestones in the near future.
Dr. Jeff Smith's Vision
Co-Founder and Chief Research Officer Dr. Jeff Smith commended Dr. Gorsuch's promotion, highlighting the importance of robust scientific leadership in translating non-clinical progress into successful clinical applications. He noted that as a frontrunner in in vivo gene editing, Precision needs to ensure its preclinical work culminates in real-world success.
Acknowledging Departures
As Precision BioSciences optimizes its leadership, it also acknowledges the retirement of Sam Wadsworth, PhD, from his Board position. Mr. Amoroso expressed gratitude for Dr. Wadsworth’s contributions to the Science and Technology Committee, wishing him well in his future endeavors. This shift is part of Precision’s strategic focus on enhancing its core capabilities to meet urgent medical needs.
About Precision BioSciences, Inc.
Precision BioSciences is dedicated to innovating life through its proprietary ARCUS genome editing platform, which excels in precision and efficacy compared to alternative technologies. The ARCUS platform has established a pipeline of in vivo gene editing candidates targeting various genetic and infectious diseases, aiming to provide lasting health solutions where conventional treatments fall short.
Frequently Asked Questions
What is the primary focus of Precision BioSciences?
Precision BioSciences focuses on in vivo gene editing to develop therapies that address genetic and infectious diseases.
What are the key changes in the leadership team?
Cindy Atwell was appointed Chief Development and Business Officer and Cassie Gorsuch was promoted to Chief Scientific Officer.
What role does the ARCUS platform play in the company's strategy?
The ARCUS platform is central to Precision BioSciences' approach, enabling targeted and efficient gene editing solutions.
How is Precision progressing with the PBGENE-HBV program?
The PBGENE-HBV program is currently undergoing Phase 1 clinical studies, with anticipated data milestones expected soon.
Why is the departure of Sam Wadsworth significant?
Dr. Wadsworth's retirement marks a transitional phase in Precision’s leadership as the company seeks to optimize its strategic direction and capabilities.
